Symbols

RNXT

RenovoRx·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RNXT

Renovorx, Inc.

A clinical-stage biopharmaceutical company that developing local therapies for solid tumors

Industry

Pharmaceutical

Established Date

12/17/2012

Listing Date

08/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.renovorx.com

Security Type

Common stock

Office address

2570 West El Camino Real, Suite 320, Mountain View, CA 94040

Business

Introduction

RenovoRx, Inc., was incorporated in Delaware on December 17, 2012. The Company is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for highly unmet medical needs with the goal of improving treatment outcomes for cancer patients undergoing treatment. The Company's proprietary Transarterial Microperfusion (TAMPT) treatment platform is designed to ensure precise treatment delivery to directly target the tumor while potentially minimizing the toxicity of the treatment relative to systemic (intravenous (referred to as "IV ") treatment).

Company Financials

EPS

RNXT has released its 2025 Q4 earnings. EPS was reported at -0.08, versus the expected -0.08, meeting expectations. The chart below visualizes how RNXT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RNXT has released its 2025 Q4 earnings report, with revenue of 238.00K, reflecting a YoY change of 453.49%, and net profit of -2.94M, showing a YoY change of -2.19%. The Sankey diagram below clearly presents RNXT's revenue sources and cost distribution.